Gregor Hasler: Three Guiding Questions — How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?

Summary

Gregor Hasler is a leading figure in psychedelic research, focusing on how substances like LSD, psilocybin, and MDMA can reshape brain function to treat mental health issues such as depression, PTSD, and addiction. His work shows that psychedelics can enhance neuroplasticity, leading to clinical improvements that may last for months or years. He has also identified mGluR5 as a biomarker for nicotine dependence, contributing significantly to psychiatric treatment advancements.

Study at a glance

Abstract

Professor Gregor Hasler stands at the forefront of revolutionary psychedelic research and neuroplasticity studies, transforming our understanding of mental health treatment through groundbreaking scientific discoveries. As Chair of Psychiatry at the University of Fribourg, Switzerland, where he directs the Molecular Psychiatry Lab, Hasler has pioneered research on how psychedelics like LSD, psilocybin, and MDMA reshape brain function to treat depression, PTSD, and addiction. His Genomic Press Interview reveals a career dedicated to uncovering rapid antidepressant mechanisms and developing innovative treatments that offer hope to millions suffering from psychiatric conditions. His interdisciplinary team investigates how psychedelics rapidly enhance neuroplasticity, with clinical improvements lasting months or years after treatment. Hasler's groundbreaking discovery of mGluR5 as a biomarker for nicotine dependence represents his greatest scientific success, demonstrating his ability to translate complex molecular research into practical clinical applications. Honored with prestigious awards including the NARSAD Independent Investigator Award and the Robert Bing Award from the Swiss Academy of Medical Sciences, he bridges rigorous neuroscience with compassionate clinical practice. His influential book Higher Self: Psychedelics in Psychotherapy captures decades of research wisdom, proposing bold visions for psychiatry's future. As former President of the Swiss Society for Drug Safety in Psychiatry and a member of the American College of Neuropsychopharmacology, Hasler ensures the safe integration of psychedelic therapies into mainstream medicine. His work on glutamate and GABA neurotransmitter systems has fundamentally changed how we understand mood disorders, offering new pathways for treatment-resistant conditions and establishing him as a transformative leader in modern psychiatry.